News Agency
Men's Weekly

Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

  • Written by PR Newswire
Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study evaluating SKY-0515, a RNA-Targeting Small Molecule for Huntington's Disease

SKY-0515 is a small molecule RNA splicing modifier developed through the company's novel SKYSTAR® platform. Having successfully advanced through single asending dose,SKY-0515 is advancing into the Multiple Ascending Dose portion of its phase 1 study. Huntington's disease is a fatal neurological disease with no curative therapies.

WALTH...

Read more: Skyhawk Therapeutics Has Advanced to the Multiple Ascending Dose Portion of its Phase 1 Study...

Steps to Take When Facing a Commercial Lease Dispute in Australia

A commercial lease dispute can disrupt business operations, especially when the business premises are central to generating revenue. This article outlines practical steps to take when a disagreement arises under a commercial lease in Australia and how, as a tenant, you can... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion